Cargando…

Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer

BACKGROUND: CDH13 is a novel tumor suppressor gene often inactivated by aberrant promoter methylation in human cancers. Previous studies have shown that CDH13 methylation correlated with advanced disease and poor prognosis in non-muscle invasive bladder cancer (NMIBC). The aim of the current study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ying-Li, Xie, Pei-Gen, Ma, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162450/
https://www.ncbi.nlm.nih.gov/pubmed/25196672
http://dx.doi.org/10.12659/MSM.892130
_version_ 1782334669147078656
author Lin, Ying-Li
Xie, Pei-Gen
Ma, Jian-Guo
author_facet Lin, Ying-Li
Xie, Pei-Gen
Ma, Jian-Guo
author_sort Lin, Ying-Li
collection PubMed
description BACKGROUND: CDH13 is a novel tumor suppressor gene often inactivated by aberrant promoter methylation in human cancers. Previous studies have shown that CDH13 methylation correlated with advanced disease and poor prognosis in non-muscle invasive bladder cancer (NMIBC). The aim of the current study was to investigate the correlations between CDH13 methylation and disease recurrence as well as progression of NMIBC. MATERIAL/METHODS: The methylation status of CDH13 in 178 NMIBC samples and 38 normal bladder epithelial tissues was examined by methylation-specific PCR (MSP), and then correlated with clinicopathological features. RESULTS: We found that CDH13 methylation occurs frequently in NMIBC, and significantly correlates with high grade, advanced stage, larger tumor size, and tumor recurrence and progression. Moreover, patients with methylated CDH13 exhibited significantly shorter recurrence-free survival (P<0.0001) and progression-free survival (P=0.0060) than patients with unmethylated CDH13. In addition, a multivariate Cox proportional hazard model analysis suggests that CDH13 methylation is an independent predictor for the recurrence (P=0.0043) and progression (P=0.0016) of NMIBC after initial transurethral resection. CONCLUSIONS: Our findings demonstrate that CDH13 methylation is a frequent event in NMIBC, and is associated with unfavorable tumor features. It should be used as an independent predictor for the recurrence and progression of NMIBC, and may be useful for the design of individualized therapeutic modalities.
format Online
Article
Text
id pubmed-4162450
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-41624502014-09-16 Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer Lin, Ying-Li Xie, Pei-Gen Ma, Jian-Guo Med Sci Monit Molecular Biology BACKGROUND: CDH13 is a novel tumor suppressor gene often inactivated by aberrant promoter methylation in human cancers. Previous studies have shown that CDH13 methylation correlated with advanced disease and poor prognosis in non-muscle invasive bladder cancer (NMIBC). The aim of the current study was to investigate the correlations between CDH13 methylation and disease recurrence as well as progression of NMIBC. MATERIAL/METHODS: The methylation status of CDH13 in 178 NMIBC samples and 38 normal bladder epithelial tissues was examined by methylation-specific PCR (MSP), and then correlated with clinicopathological features. RESULTS: We found that CDH13 methylation occurs frequently in NMIBC, and significantly correlates with high grade, advanced stage, larger tumor size, and tumor recurrence and progression. Moreover, patients with methylated CDH13 exhibited significantly shorter recurrence-free survival (P<0.0001) and progression-free survival (P=0.0060) than patients with unmethylated CDH13. In addition, a multivariate Cox proportional hazard model analysis suggests that CDH13 methylation is an independent predictor for the recurrence (P=0.0043) and progression (P=0.0016) of NMIBC after initial transurethral resection. CONCLUSIONS: Our findings demonstrate that CDH13 methylation is a frequent event in NMIBC, and is associated with unfavorable tumor features. It should be used as an independent predictor for the recurrence and progression of NMIBC, and may be useful for the design of individualized therapeutic modalities. International Scientific Literature, Inc. 2014-09-04 /pmc/articles/PMC4162450/ /pubmed/25196672 http://dx.doi.org/10.12659/MSM.892130 Text en © Med Sci Monit, 2014 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Molecular Biology
Lin, Ying-Li
Xie, Pei-Gen
Ma, Jian-Guo
Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title_full Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title_fullStr Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title_full_unstemmed Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title_short Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
title_sort aberrant methylation of cdh13 is a potential biomarker for predicting the recurrence and progression of non-muscle-invasive bladder cancer
topic Molecular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162450/
https://www.ncbi.nlm.nih.gov/pubmed/25196672
http://dx.doi.org/10.12659/MSM.892130
work_keys_str_mv AT linyingli aberrantmethylationofcdh13isapotentialbiomarkerforpredictingtherecurrenceandprogressionofnonmuscleinvasivebladdercancer
AT xiepeigen aberrantmethylationofcdh13isapotentialbiomarkerforpredictingtherecurrenceandprogressionofnonmuscleinvasivebladdercancer
AT majianguo aberrantmethylationofcdh13isapotentialbiomarkerforpredictingtherecurrenceandprogressionofnonmuscleinvasivebladdercancer